Diligence memo · auto-generated · as of July 3, 2026
AME Therapeutics, Inc.
AME Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
AME Therapeutics, Inc. operates in Pharma, based in SANTA MONICA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AME Therapeutics, Inc. has raised $1.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2021-06-08.
Most recent recorded round closed around 2021-06-08.
Valuation (modeled)modeled
Provath models AME Therapeutics, Inc. at approximately $25M (range $811K–$153M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.44× the median modeled value of Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 5.1 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 37% of Pharma peers (310 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Zoo Pharma Dynamics Inc., Pharma-Labs Finance LLC, FSD Pharma Inc., Deepbiome Therapeutics, Inc., Pykus Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.